Text Size

Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension

This study has been completed.
Sponsor:
Information provided by:
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
NCT00858702
First received: March 9, 2009
Last updated: September 18, 2009
Last verified: September 2009
History of Changes
Results First Received: July 16, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Hypertension
Interventions: Drug: olmesartan medoxomil and a CCB
Drug: olmesartan medoxomil and a diuretic

  Participant Flow
  Show Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Olmesartan Tablets and a Calcium Channel Blocker Tablet olmesartan medoxomil tablets and a calcium channel blocker tablet, once daily for 8 weeks
Olmesartan Medoxomil Tablets and a Diuretic olmesartan medoxomil tablets and a diuretic once daily for 8 weeks
Total Total of all reporting groups

Baseline Measures
    Olmesartan Tablets and a Calcium Channel Blocker Tablet     Olmesartan Medoxomil Tablets and a Diuretic     Total  
Number of Participants  
[units: participants]
 		  53     52     105  
Age  
[units: years]
Mean ± Standard Deviation 		  56.2  ± 11.2     57.4  ± 9.4     56.8  ± 10.3  
Gender  
[units: participants]
 		     
Female     22     20     42  
Male     31     32     63  
Race/Ethnicity, Customized  
[units: Participants]
 		     
Japanese     53     52     105  
Region of Enrollment  
[units: participants]
 		     
Japan     53     52     105  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85   [ Time Frame: Baseline to week 8 ]
  Show Outcome Measure 1

2.  Secondary:   Percentage of Patients With Drug-related Adverse Events (Subjective Symptoms/Objective Findings)   [ Time Frame: At week 8 ]
  Show Outcome Measure 2

3.  Secondary:   Percent of Patients With Drug-related Adverse Events (Laboratory Changes in Clinical Laboratory Values)   [ Time Frame: At week 8 ]
  Show Outcome Measure 3


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Howard Kessler
Organization: Daiichi Sankyo
phone: 732-590-5032
e-mail: hmkessler@dsi.com


No publications provided


Responsible Party: Yoshihiro Kakehi, Daiichi Sankyo Co., Ltd.
ClinicalTrials.gov Identifier: NCT00858702     History of Changes
Other Study ID Numbers: OLM004-071
Study First Received: March 9, 2009
Results First Received: July 16, 2009
Last Updated: September 18, 2009
Health Authority: Japan: Ministry of Health, Labor and Welfare